Literature DB >> 30312645

Androgens in women: Hormone-modulating therapies for skin disease.

Sarah Azarchi1, Amanda Bienenfeld1, Kristen Lo Sicco2, Shari Marchbein2, Jerry Shapiro2, Arielle R Nagler3.   

Abstract

Androgen-mediated cutaneous disorders (AMCDs) in women, including acne, hirsutism, and female pattern hair loss, can be treated with hormone-modulating therapies. In the second article in this Continuing Medical Education series, we discuss the hormone-modulating therapies available to dermatologists for the treatment of AMCDs, including combined oral contraceptives, spironolactone, finasteride, dutasteride, and flutamide. Available hormone-modulating treatments used for each AMCDs are reviewed, along with mechanisms of androgen modulation, safety profile, contraindications, monitoring parameters, and evidence of efficacy. Medications discussed include those that are approved by the US Food and Drug Administration for certain AMCDs and some that are used off-label. Despite the ubiquity of hormone-modulating therapies used for AMCDs, this review highlights the need for more rigorous studies to evaluate these therapies for acne, hirsutism, and female pattern hair loss. Published by Elsevier Inc.

Entities:  

Keywords:  acne; androgen receptor; androgenetic alopecia; androgens; combined oral contraceptive; congenital adrenal hyperplasia; dutasteride; female pattern hair loss; finasteride; flutamide; hirsutism; polycystic ovary syndrome; spironolactone

Mesh:

Substances:

Year:  2018        PMID: 30312645     DOI: 10.1016/j.jaad.2018.08.061

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

1.  Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target.

Authors:  Silvia Giatti; Alessandro Di Domizio; Silvia Diviccaro; Eva Falvo; Donatella Caruso; Alessandro Contini; Roberto Cosimo Melcangi
Journal:  J Med Chem       Date:  2021-04-12       Impact factor: 7.446

2.  Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.

Authors:  Xuelei Liang; Yuan Chang; Haixuan Wu; Yi Liu; Jian Zhao; Leyi Wang; Fenglin Zhuo
Journal:  Front Med (Lausanne)       Date:  2022-07-11

Review 3.  Spironolactone and XPB: An Old Drug with a New Molecular Target.

Authors:  Ryan D Gabbard; Robert R Hoopes; Michael G Kemp
Journal:  Biomolecules       Date:  2020-05-13

4.  Spironolactone hyaluronic acid enriched cerosomes (HAECs) for topical management of hirsutism: in silico studies, statistical optimization, ex vivo, and in vivo studies.

Authors:  Rofida Albash; Abdurrahman M Fahmy; Mohammed I A Hamed; Khaled M Darwish; Rania Moataz El-Dahmy
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.